3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Multiple Myeloma
3
Lymphoma
3
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Vascular Diseases
1
Thrombocytosis
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hemorrhagic Disorders
1
Hematologic Neoplasms
1
Interventions
Brentuximab Vedotin
21
Cyclophosphamide
17
Rituximab
11
fludarabine
9
Mycophenolic Acid
9
pirtobrutinib
7
dacetuzumab
7
Busulfan
7
fludarabine phosphate
6
Tacrolimus
6
Melphalan
6
Whole-Body Irradiation
5
Doxorubicin
5
Vincristine
4
Prednisone
4
Mesna
4
Etoposide
4
Bone Marrow Transplantation
4
Bendamustine Hydrochloride
4
ibrutinib
3
Thiotepa
3
Sirolimus
3
Cyclosporine
3
Bortezomib
3
ponatinib
2
Vorinostat
2
Stem Cell Transplantation
2
Rifampin
2
Platelet Transfusion
2
Peripheral Blood Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
Erlotinib Hydrochloride
×
Lymphoid
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled